LYEL241220P7500
- 0.00
- 0.000.00%
Lyell Immunopharma Newsroom
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024
Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma
Express News | Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA
Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
Express News | Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting
Express News | Lyell Immunopharma Files Prospectus Related to Resale From Time to Time by Selling Stockholders of up to 37.5 Mln Shares of Common Stock - SEC Filing
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
Express News | HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Lyell Immunopharma Analyst Ratings
Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges
Positive Week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) Institutional Investors Who Lost 26% Over the Past Year
Lyell Immunopharma Reports Q3 Net Loss $44.6M Vs. $50.9M Last Year
Express News | Lyell Immunopharma : Our Strong Cash Position Enables US to Advance Our Pipeline Through Important Clinical Milestones and Fund Operations Into 2027
Lyell Immunopharma | 10-Q: Q3 2024 Earnings Report
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $34,000
Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
Express News | Lyell Immunopharma Q3 Revenue USD 34 Thousand
Express News | Lyell Immunopharma Q3 Operating Income USD -50.505 Million
Express News | Lyell Immunopharma Q3 Operating Expenses USD 50.539 Million